Bayer AG
XETRA:BAYN
Bayer AG
XETRA:BAYN
Price:
55.55 EUR
-0.7%
Market Closed
Updated:
Mar 25, 2023
Section:
Relative Value
The Relative Value of one
BAYN
stock under the Base Case scenario is
94.39
EUR.
Compared to the current market price of 55.55 EUR,
Bayer AG
is
Undervalued by 41%.
Relative valuation is one of two methods of placing a monetary value on a company; the other is Discounted Cash Flow valuation method. We use a combination of these two methods to calculate the Intrinsic Value of stock as accurately as possible.
Relative Valuation FAQ:
BAYN
Relative Value
Base Case
94.39
EUR
Undervaluation 41%
Valuation Multiples
Multiples Across Competitors
BAYN Competitors Multiples
Bayer AG Competitors
Bayer AG Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
Bayer AG
XETRA:BAYN
|
54.6B EUR | 1.1 | 13.2 | 5.8 | 11.1 | |
| ZA |
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
8T Zac | 0 | 0 | 0 | 0 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
476B USD | 5 | 26.5 | 14.4 | 18.2 | |
| DK |
|
Novo Nordisk A/S
NYSE:NVO
|
348B USD | 13.6 | 43.4 | 29.4 | 32.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
319B USD | 11.2 | 51.1 | 33.9 | 40.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
266B USD | 4.5 | 18.3 | 11.6 | 13.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
227B USD | 2.3 | 7.2 | 5.6 | 6.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
206B CHF | 3.2 | 14.1 | 9.2 | 11.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
172B GBP | 4.7 | 63.9 | 142.2 | 235.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
162B CHF | 3.4 | 25.4 | 8.9 | 13.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
140B USD | 3 | 22.2 | 7.6 | 14.3 |
| P/S Multiple | Revenue Growth | |||
|---|---|---|---|---|
| DE |
|
Bayer AG
XETRA:BAYN
|
1.1
|
8%
|
| ZA |
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
Not Available |
20%
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
5
|
10%
|
| DK |
|
Novo Nordisk A/S
NYSE:NVO
|
13.6
|
47%
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
11.2
|
55%
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
4.5
|
11%
|
| US |
|
Pfizer Inc
NYSE:PFE
|
2.3
|
-28%
|
| CH |
|
Roche Holding AG
SIX:ROG
|
3.2
|
4%
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
4.7
|
25%
|
| CH |
|
Novartis AG
SIX:NOVN
|
3.4
|
10%
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
3
|
7%
|
| P/E Multiple | Earnings Growth | |||
|---|---|---|---|---|
| DE |
|
Bayer AG
XETRA:BAYN
|
13.2
|
104%
|
| ZA |
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
Not Available |
31%
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
26.5
|
67%
|
| DK |
|
Novo Nordisk A/S
NYSE:NVO
|
43.4
|
68%
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
51.1
|
145%
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
18.3
|
68%
|
| US |
|
Pfizer Inc
NYSE:PFE
|
7.2
|
-30%
|
| CH |
|
Roche Holding AG
SIX:ROG
|
14.1
|
25%
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
63.9
|
374%
|
| CH |
|
Novartis AG
SIX:NOVN
|
25.4
|
135%
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
22.2
|
184%
|
| EV/EBITDA Multiple | EBITDA Growth | |||
|---|---|---|---|---|
| DE |
|
Bayer AG
XETRA:BAYN
|
5.8
|
7%
|
| ZA |
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
Not Available |
50%
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
14.4
|
13%
|
| DK |
|
Novo Nordisk A/S
NYSE:NVO
|
29.4
|
53%
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
33.9
|
90%
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
11.6
|
32%
|
| US |
|
Pfizer Inc
NYSE:PFE
|
5.6
|
-34%
|
| CH |
|
Roche Holding AG
SIX:ROG
|
9.2
|
16%
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
142.2
|
58%
|
| CH |
|
Novartis AG
SIX:NOVN
|
8.9
|
8%
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
7.6
|
0%
|
| EV/EBIT Multiple | EBIT Growth | |||
|---|---|---|---|---|
| DE |
|
Bayer AG
XETRA:BAYN
|
11.1
|
46%
|
| ZA |
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
Not Available |
28%
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
18.2
|
22%
|
| DK |
|
Novo Nordisk A/S
NYSE:NVO
|
32.3
|
51%
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
40.1
|
101%
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
13.9
|
42%
|
| US |
|
Pfizer Inc
NYSE:PFE
|
6.3
|
-36%
|
| CH |
|
Roche Holding AG
SIX:ROG
|
11.1
|
23%
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
235.8
|
132%
|
| CH |
|
Novartis AG
SIX:NOVN
|
13.8
|
39%
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
14.3
|
77%
|
